Zhitong Finance App News, Zhongguancun (000931.SZ) issued an announcement. Beijing Huasu Pharmaceutical Co., Ltd., a subsidiary of the company, recently received the “Notice of Acceptance” issued by the State Drug Administration, and the marketing license application for dortinolide tablets (specifications: 1 mg, 2 mg) was accepted. Dotinolide tablets are suitable for patients with gout with hyperuricemia. They can selectively inhibit URAT1, a transporter of uric acid reabsorption in the kidneys, promote the excretion of uric acid filtered by glomeruli through urine, and reduce blood uric acid levels.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.